NPS Pharmaceuticals (NPSP) 45.88 $NPSP
Today's Market: Earnings Moving These Stocks, M&A In Pharma And Big Management Shakeups
Matthew Smith - at Seeking Alpha - Fri Feb 13, 8:56AM CST
VRX: 167.00 (-0.50), CAG: 34.83 (-1.59), SHPG: 239.82 (+6.11), SLXP: 152.35 (+3.17), NPSP: 45.88 (+0.03), KRFT: 64.42 (-1.75), AIG: 53.96 (+1.51), ZNGA: 2.24 (-0.42), KING: 16.70 (+1.96)
Shire Misses on Q4 Earnings, Revenues Beat; Shares Rise - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Feb 13, 8:54AM CST
Shire plc (SHPG) reported fourth-quarter 2014 earnings (excluding special items and amortization) of $2.63 per American Depositary Share (ADS), missed the Zacks Consensus Estimate of $2.66.
SHPG: 239.82 (+6.11), SCMP: 15.32 (+0.04), NPSP: 45.88 (+0.03), ABBV: 58.05 (+1.00)
Shire rises on NPS potential
at Investor's Business Daily - Thu Feb 12, 5:30PM CST
The Irish drugmaker reported a 19% jump in Q4 earnings to $2.63 per American depositary share, but fell short of views by 5 cents. Revenue climbed 19% to $1.58 bil, topping views. The results were overshadowed by excitement over the company's $5.2...
SHPG: 239.82 (+6.11), NPSP: 45.88 (+0.03)
Shire Moves Up On NPS Potential; Q4 Earnings Miss
at Investor's Business Daily - Thu Feb 12, 9:45AM CST
Shares of Shire (SHPG) moved higher early Thursday as the Irish drugmaker's better-than-expected quarterly revenue and upbeat 2015 outlook offset an earnings miss. Reporting before the open, Shire logged fourth-quarter earnings of $2.63 per American...
AGN: 229.49 (+1.87), VRX: 167.00 (-0.50), SHPG: 239.82 (+6.11), SLXP: 152.35 (+3.17), NPSP: 45.88 (+0.03), ABBV: 58.05 (+1.00)
63.3% Return Seen to Date on SmarTrend NPS Pharmaceuticals Call (NPSP)
Comtex SmarTrend(R) - Wed Feb 11, 9:32AM CST
SmarTrend identified an Uptrend for NPS Pharmaceuticals (NASDAQ:NPSP) on October 20th, 2014 at $28.10. In approximately 4 months, NPS Pharmaceuticals has returned 63.29% as of today's recent price of $45.88.
NPSP: 45.88 (+0.03)
Congratulations Covidien: You Escaped In Time
Chris DeMuth Jr. - Seeking Alpha - Wed Feb 11, 8:19AM CST
Originally published on February 4, 2015 The Shakedown In 2014, Obama vowed to punish tax inverting companies by any means necessary - inside and outside of legislation. He took scalps including Shire (NASDAQ: SHPG ) and Walgreens (NASDAQ: WBA...
VRX: 167.00 (-0.50), WBA: 78.73 (-1.23), MDT: 75.26 (+0.33), COV: 106.71 (-1.36), SHPG: 239.82 (+6.11), SLXP: 152.35 (+3.17), NPSP: 45.88 (+0.03), ABBV: 58.05 (+1.00)
Biotech Stocks Review - Arena Pharma, Amgen, NPS Pharma, ZIOPHARM Oncology, and Advaxis
PR Newswire - Fri Feb 06, 8:00AM CST
Investor-Edge has initiated coverage on the following equities: Arena Pharmaceuticals Inc. (NASDAQ: ARNA), Amgen Inc. (NASDAQ: AMGN), NPS Pharmaceuticals Inc. (NASDAQ: NPSP), ZIOPHARM Oncology Inc. (NASDAQ: ZIOP), and Advaxis Inc. (NASDAQ: ADXS). Free research report on Arena Pharma can be accessed at http://get.Investor-Edge.com/pdf/?c=Arena%20P...amp;s=ARNA. On Thursday, February 05, 2015, the NASDAQ Composite ended at 4,765.10, up 1.03%, the Dow Jones Industrial Average advanced 1.20%, to finish the day at 17,884.88, and the S&P 500 closed at 2,062.52, up 1.03%. The gains were broad based as all the sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 813.68, up 1.64%, with the index also advancing 4.56% in the last three months. Register for your complimentary reports at the links given below.
ADXS: 7.18 (+0.06), ZIOP: 9.64 (-0.35), NPSP: 45.88 (+0.03), AMGN: 153.48 (+0.30), ARNA: 4.55 (+0.02)
'Mad Money' Lightning Round: Ambarella Is Like Putting a Gun to Your Head
at The Street - Thu Feb 05, 5:00AM CST
Cramer says take the money and run on NPS Pharmaceuticals, stay away from VMware and he missed the boat on OvaScience.
AMBA: 50.71 (-4.46), BX: 37.40 (+0.49), VMW: 84.68 (+1.06), OVAS: 44.32 (+0.87), NBR: 12.73 (+0.52), ALK: 62.56 (-0.19), HPQ: 38.56 (+0.19), SLB: 88.38 (+2.42), LUV: 43.30 (-0.20), HAIN: 59.48 (+0.45), SSYS: 67.16 (-0.34), NPSP: 45.88 (+0.03), PPC: 26.75 (+0.77), FLT: 150.37 (+1.15), MD: 71.32 (-0.06)
Blackstone Is An Excellent Holding - Cramer's Lightning Round (2/4/15)
SA Editor Mohit Manghnani - at Seeking Alpha - Thu Feb 05, 4:21AM CST
Stocks discussed on the Lightning Round segment of Jim Cramer's Mad Money Program, Wednesday, February 4. Bullish Calls: Alaska Air (NYSE: ALK ): " I like Alaska Air and I like Southwest Airlines (NYSE: LUV )." OvaScience (NASDAQ:...
AMBA: 50.71 (-4.46), BX: 37.40 (+0.49), OVAS: 44.32 (+0.87), VMW: 84.68 (+1.06), NBR: 12.73 (+0.52), ALK: 62.56 (-0.19), HPQ: 38.56 (+0.19), SLB: 88.38 (+2.42), LUV: 43.30 (-0.20), SSYS: 67.16 (-0.34), PPC: 26.75 (+0.77), NPSP: 45.88 (+0.03), FLT: 150.37 (+1.15), MD: 71.32 (-0.06)
Jim Cramer's 'Mad Money' Recap: Zombie Stocks That Will Rise From the Dead
at The Street - Wed Feb 04, 7:26PM CST
Many of the stocks hit hard Wednesday will rise again soon enough, Cramer says.
KMI: 41.97 (+0.21), MMM: 165.94 (+0.03), BX: 37.40 (+0.49), VMW: 84.68 (+1.06), OVAS: 44.32 (+0.87), NKE: 92.04 (+0.04), FRPT: 16.78 (-0.12), NBR: 12.73 (+0.52), WYNN: 159.34 (+4.62), RL: 135.20 (-0.60), UPS: 101.79 (+0.38), SLB: 88.38 (+2.42), LUV: 43.30 (-0.20), WHR: 213.23 (+0.18), JNJ: 99.62 (+1.18), BC: 55.30 (+0.61), CMG: 674.89 (+4.60), SSYS: 67.16 (-0.34), PPC: 26.75 (+0.77), NPSP: 45.88 (+0.03), DG: 68.82 (+1.23), CAT: 85.13 (+1.60), MD: 71.32 (-0.06), AAPL: 127.08 (+0.62), REGN: 402.40 (+0.66), WFM: 56.15 (-0.15), AMBA: 50.71 (-4.46), NSC: 109.91 (-0.17), MCK: 224.89 (+0.12), NUE: 48.90 (+0.55), HAL: 44.19 (+1.42), DIS: 104.17 (+0.59), COP: 69.88 (+1.84), BMY: 60.04 (+0.56), ALK: 62.56 (-0.19), HPQ: 38.56 (+0.19), CELG: 115.88 (+0.16), HAIN: 59.48 (+0.45), TTWO: 28.40 (+0.96), GILD: 101.90 (+1.10), MCD: 95.65 (+0.56), FLT: 150.37 (+1.15), PG: 85.90 (-0.13)
Why NPS Pharmaceuticals, Inc. Shares Soared 28% in January
Sean Williams, The Motley Fool - Motley Fool - Wed Feb 04, 8:55AM CST
NPSP data by YCharts What: Shares of NPS Pharmaceuticals , a biopharmaceutical company focused on developing therapies targeted at rare and orphan-class diseases, soared by 28% in January, per S&P Capital IQ , after a double dose of...
SHPG: 239.82 (+6.11), NPSP: 45.88 (+0.03)
Shire's Vyvanse Label Expanded for Binge-Eating Disorder - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Feb 02, 2:45PM CST
Shire's (SHPG) Vyvanse gets further FDA approval; adds binge eating disorder to its label.
SHPG: 239.82 (+6.11), PETX: 16.52 (-0.10), NPSP: 45.88 (+0.03), BIOD: 1.38 (-0.14)
Lifshitz & Miller Law Firm Announces Investigation of Calavo Growers, Inc., Courier Corporation, Five Below, Inc., MeadWestvaco Corporation, National Bancshares Corporation, NPS Pharmaceuticals, Inc. and Silicon Image, Inc.
PR Newswire - Thu Jan 29, 4:55PM CST
Calavo Growers, Inc.
SIMG: 7.25 (-0.01), MWV: 53.91 (+0.59), NPSP: 45.88 (+0.03), CVGW: 41.64 (+0.19), FIVE: 33.01 (+0.11), CRRC: 22.96 (+0.22)
NPSP INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Investors of NPS Pharmaceuticals Inc. of Class Action Against the Board of the Company Concerning the Fairness of the Sale of the Company to Shire plc-- NPSP
GlobeNewswire - Thu Jan 29, 2:24PM CST
Levi & Korsinsky notifies investors of NPS Pharmaceuticals Inc. ("NPS Pharmaceuticals" or "the Company"
(Nasdaq:NPSP) of claims of breaches of fiduciary duty and other violations of state law against the board of directors of the Company in connection with the sale of the Company to Shire plc. A complaint was filed in Delaware state court.
SHPG: 239.82 (+6.11), NPSP: 45.88 (+0.03)
Shares of NPSP Up 63.4% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Tue Jan 27, 4:39PM CST
SmarTrend identified an Uptrend for NPS Pharmaceuticals (NASDAQ:NPSP) on October 20th, 2014 at $28.10. In approximately 3 months, NPS Pharmaceuticals has returned 63.45% as of today's recent price of $45.92.
NPSP: 45.88 (+0.03)
NPS Pharmaceuticals' Natpara Approved with Boxed Warning - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jan 27, 4:38PM CST
NPS Pharmaceuticals' (NPSP) Natpara gained FDA approval as an adjunct treatment to calcium and vitamin D to control hypocalcemia in patients suffering from hypoparathyroidism.
ENDP: 84.01 (+1.12), SHPG: 239.82 (+6.11), NPSP: 45.88 (+0.03), BIOD: 1.38 (-0.14)
NPS PHARMACEUTICALS INVESTOR ALERT: Faruqi & Faruqi, LLP Announces the Investigation of NPS Pharmaceuticals, Inc. (NPSP) Over the Proposed Sale of the Company to Shire PLC
Business Wire - Tue Jan 27, 1:37PM CST
Juan E. Monteverde, a partner at Faruqi & Faruqi, LLP, a leading national securities firm headquartered in New York City, is investigating the Board of Directors of NPS Pharmaceuticals, Inc. ("NPS" or the "Company" (Nasdaq: NPSP) for potential breaches of fiduciary duties in connection with the sale of the Company to Shire PLC ("Shire" (Nasdaq: SHPG) for approximately $5.2 billion. The Company's stockholders will only receive $46 for each share of NPS common stock they own. Given the recent FDA approval of NPS's Natpara, a drug to control low blood calcium levels related to hypoparathyroidism, the Company's value could be much higher than the tender offer price.
SHPG: 239.82 (+6.11), NPSP: 45.88 (+0.03)
Pfizer, Inc. Should Forget AstraZeneca and Buy This Company Instead
Motley Fool Staff, Leo Sun, George Budwell, and Cheryl Swanson - Motley Fool - Tue Jan 27, 6:56AM CST
Source: Pfizer Inc via Facebook. Pfizer Inc. 's failed bid to acquire U.K.-based AstraZeneca last year suggests that dealmakers are hard at work identifying new acquisition targets for the global drugmaker. If so, investors are right to ponder...
BIIB: 391.66 (-0.45), ESRX: 84.90 (+0.40), ISIS: 63.86 (-0.43), GILD: 101.90 (+1.10), SHPG: 239.82 (+6.11), PFE: 34.64 (-0.23), AZN: 69.96 (+0.20), NPSP: 45.88 (+0.03), ABBV: 58.05 (+1.00), GSK: 47.94 (+1.99)
Shire's Elvanse Gets Positive Response for ADHD in Adults - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jan 26, 4:20PM CST
Shire plc (SHPG) recently announced that it has received a positive response from the European Decentralised Procedure for the use of ADHD drug Elvanse in adults in three European countries.
SHPG: 239.82 (+6.11), SCMP: 15.32 (+0.04), NPSP: 45.88 (+0.03), BIOD: 1.38 (-0.14)
Today's Market: Earnings Moving These Stocks, M&A In Pharma And Big Management Shakeups
Matthew Smith - at Seeking Alpha - Fri Feb 13, 8:56AM CST
VRX: 167.00 (-0.50), CAG: 34.83 (-1.59), SHPG: 239.82 (+6.11), SLXP: 152.35 (+3.17), NPSP: 45.88 (+0.03), KRFT: 64.42 (-1.75), AIG: 53.96 (+1.51), ZNGA: 2.24 (-0.42), KING: 16.70 (+1.96)
Shire Misses on Q4 Earnings, Revenues Beat; Shares Rise - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Feb 13, 8:54AM CST
Shire plc (SHPG) reported fourth-quarter 2014 earnings (excluding special items and amortization) of $2.63 per American Depositary Share (ADS), missed the Zacks Consensus Estimate of $2.66.
SHPG: 239.82 (+6.11), SCMP: 15.32 (+0.04), NPSP: 45.88 (+0.03), ABBV: 58.05 (+1.00)
Shire rises on NPS potential
at Investor's Business Daily - Thu Feb 12, 5:30PM CST
The Irish drugmaker reported a 19% jump in Q4 earnings to $2.63 per American depositary share, but fell short of views by 5 cents. Revenue climbed 19% to $1.58 bil, topping views. The results were overshadowed by excitement over the company's $5.2...
SHPG: 239.82 (+6.11), NPSP: 45.88 (+0.03)
Shire Moves Up On NPS Potential; Q4 Earnings Miss
at Investor's Business Daily - Thu Feb 12, 9:45AM CST
Shares of Shire (SHPG) moved higher early Thursday as the Irish drugmaker's better-than-expected quarterly revenue and upbeat 2015 outlook offset an earnings miss. Reporting before the open, Shire logged fourth-quarter earnings of $2.63 per American...
AGN: 229.49 (+1.87), VRX: 167.00 (-0.50), SHPG: 239.82 (+6.11), SLXP: 152.35 (+3.17), NPSP: 45.88 (+0.03), ABBV: 58.05 (+1.00)
63.3% Return Seen to Date on SmarTrend NPS Pharmaceuticals Call (NPSP)
Comtex SmarTrend(R) - Wed Feb 11, 9:32AM CST
SmarTrend identified an Uptrend for NPS Pharmaceuticals (NASDAQ:NPSP) on October 20th, 2014 at $28.10. In approximately 4 months, NPS Pharmaceuticals has returned 63.29% as of today's recent price of $45.88.
NPSP: 45.88 (+0.03)
Congratulations Covidien: You Escaped In Time
Chris DeMuth Jr. - Seeking Alpha - Wed Feb 11, 8:19AM CST
Originally published on February 4, 2015 The Shakedown In 2014, Obama vowed to punish tax inverting companies by any means necessary - inside and outside of legislation. He took scalps including Shire (NASDAQ: SHPG ) and Walgreens (NASDAQ: WBA...
VRX: 167.00 (-0.50), WBA: 78.73 (-1.23), MDT: 75.26 (+0.33), COV: 106.71 (-1.36), SHPG: 239.82 (+6.11), SLXP: 152.35 (+3.17), NPSP: 45.88 (+0.03), ABBV: 58.05 (+1.00)
Biotech Stocks Review - Arena Pharma, Amgen, NPS Pharma, ZIOPHARM Oncology, and Advaxis
PR Newswire - Fri Feb 06, 8:00AM CST
Investor-Edge has initiated coverage on the following equities: Arena Pharmaceuticals Inc. (NASDAQ: ARNA), Amgen Inc. (NASDAQ: AMGN), NPS Pharmaceuticals Inc. (NASDAQ: NPSP), ZIOPHARM Oncology Inc. (NASDAQ: ZIOP), and Advaxis Inc. (NASDAQ: ADXS). Free research report on Arena Pharma can be accessed at http://get.Investor-Edge.com/pdf/?c=Arena%20P...amp;s=ARNA. On Thursday, February 05, 2015, the NASDAQ Composite ended at 4,765.10, up 1.03%, the Dow Jones Industrial Average advanced 1.20%, to finish the day at 17,884.88, and the S&P 500 closed at 2,062.52, up 1.03%. The gains were broad based as all the sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 813.68, up 1.64%, with the index also advancing 4.56% in the last three months. Register for your complimentary reports at the links given below.
ADXS: 7.18 (+0.06), ZIOP: 9.64 (-0.35), NPSP: 45.88 (+0.03), AMGN: 153.48 (+0.30), ARNA: 4.55 (+0.02)
'Mad Money' Lightning Round: Ambarella Is Like Putting a Gun to Your Head
at The Street - Thu Feb 05, 5:00AM CST
Cramer says take the money and run on NPS Pharmaceuticals, stay away from VMware and he missed the boat on OvaScience.
AMBA: 50.71 (-4.46), BX: 37.40 (+0.49), VMW: 84.68 (+1.06), OVAS: 44.32 (+0.87), NBR: 12.73 (+0.52), ALK: 62.56 (-0.19), HPQ: 38.56 (+0.19), SLB: 88.38 (+2.42), LUV: 43.30 (-0.20), HAIN: 59.48 (+0.45), SSYS: 67.16 (-0.34), NPSP: 45.88 (+0.03), PPC: 26.75 (+0.77), FLT: 150.37 (+1.15), MD: 71.32 (-0.06)
Blackstone Is An Excellent Holding - Cramer's Lightning Round (2/4/15)
SA Editor Mohit Manghnani - at Seeking Alpha - Thu Feb 05, 4:21AM CST
Stocks discussed on the Lightning Round segment of Jim Cramer's Mad Money Program, Wednesday, February 4. Bullish Calls: Alaska Air (NYSE: ALK ): " I like Alaska Air and I like Southwest Airlines (NYSE: LUV )." OvaScience (NASDAQ:...
AMBA: 50.71 (-4.46), BX: 37.40 (+0.49), OVAS: 44.32 (+0.87), VMW: 84.68 (+1.06), NBR: 12.73 (+0.52), ALK: 62.56 (-0.19), HPQ: 38.56 (+0.19), SLB: 88.38 (+2.42), LUV: 43.30 (-0.20), SSYS: 67.16 (-0.34), PPC: 26.75 (+0.77), NPSP: 45.88 (+0.03), FLT: 150.37 (+1.15), MD: 71.32 (-0.06)
Jim Cramer's 'Mad Money' Recap: Zombie Stocks That Will Rise From the Dead
at The Street - Wed Feb 04, 7:26PM CST
Many of the stocks hit hard Wednesday will rise again soon enough, Cramer says.
KMI: 41.97 (+0.21), MMM: 165.94 (+0.03), BX: 37.40 (+0.49), VMW: 84.68 (+1.06), OVAS: 44.32 (+0.87), NKE: 92.04 (+0.04), FRPT: 16.78 (-0.12), NBR: 12.73 (+0.52), WYNN: 159.34 (+4.62), RL: 135.20 (-0.60), UPS: 101.79 (+0.38), SLB: 88.38 (+2.42), LUV: 43.30 (-0.20), WHR: 213.23 (+0.18), JNJ: 99.62 (+1.18), BC: 55.30 (+0.61), CMG: 674.89 (+4.60), SSYS: 67.16 (-0.34), PPC: 26.75 (+0.77), NPSP: 45.88 (+0.03), DG: 68.82 (+1.23), CAT: 85.13 (+1.60), MD: 71.32 (-0.06), AAPL: 127.08 (+0.62), REGN: 402.40 (+0.66), WFM: 56.15 (-0.15), AMBA: 50.71 (-4.46), NSC: 109.91 (-0.17), MCK: 224.89 (+0.12), NUE: 48.90 (+0.55), HAL: 44.19 (+1.42), DIS: 104.17 (+0.59), COP: 69.88 (+1.84), BMY: 60.04 (+0.56), ALK: 62.56 (-0.19), HPQ: 38.56 (+0.19), CELG: 115.88 (+0.16), HAIN: 59.48 (+0.45), TTWO: 28.40 (+0.96), GILD: 101.90 (+1.10), MCD: 95.65 (+0.56), FLT: 150.37 (+1.15), PG: 85.90 (-0.13)
Why NPS Pharmaceuticals, Inc. Shares Soared 28% in January
Sean Williams, The Motley Fool - Motley Fool - Wed Feb 04, 8:55AM CST
NPSP data by YCharts What: Shares of NPS Pharmaceuticals , a biopharmaceutical company focused on developing therapies targeted at rare and orphan-class diseases, soared by 28% in January, per S&P Capital IQ , after a double dose of...
SHPG: 239.82 (+6.11), NPSP: 45.88 (+0.03)
Shire's Vyvanse Label Expanded for Binge-Eating Disorder - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Feb 02, 2:45PM CST
Shire's (SHPG) Vyvanse gets further FDA approval; adds binge eating disorder to its label.
SHPG: 239.82 (+6.11), PETX: 16.52 (-0.10), NPSP: 45.88 (+0.03), BIOD: 1.38 (-0.14)
Lifshitz & Miller Law Firm Announces Investigation of Calavo Growers, Inc., Courier Corporation, Five Below, Inc., MeadWestvaco Corporation, National Bancshares Corporation, NPS Pharmaceuticals, Inc. and Silicon Image, Inc.
PR Newswire - Thu Jan 29, 4:55PM CST
Calavo Growers, Inc.
SIMG: 7.25 (-0.01), MWV: 53.91 (+0.59), NPSP: 45.88 (+0.03), CVGW: 41.64 (+0.19), FIVE: 33.01 (+0.11), CRRC: 22.96 (+0.22)
NPSP INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Investors of NPS Pharmaceuticals Inc. of Class Action Against the Board of the Company Concerning the Fairness of the Sale of the Company to Shire plc-- NPSP
GlobeNewswire - Thu Jan 29, 2:24PM CST
Levi & Korsinsky notifies investors of NPS Pharmaceuticals Inc. ("NPS Pharmaceuticals" or "the Company"
(Nasdaq:NPSP) of claims of breaches of fiduciary duty and other violations of state law against the board of directors of the Company in connection with the sale of the Company to Shire plc. A complaint was filed in Delaware state court. SHPG: 239.82 (+6.11), NPSP: 45.88 (+0.03)
Shares of NPSP Up 63.4% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Tue Jan 27, 4:39PM CST
SmarTrend identified an Uptrend for NPS Pharmaceuticals (NASDAQ:NPSP) on October 20th, 2014 at $28.10. In approximately 3 months, NPS Pharmaceuticals has returned 63.45% as of today's recent price of $45.92.
NPSP: 45.88 (+0.03)
NPS Pharmaceuticals' Natpara Approved with Boxed Warning - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jan 27, 4:38PM CST
NPS Pharmaceuticals' (NPSP) Natpara gained FDA approval as an adjunct treatment to calcium and vitamin D to control hypocalcemia in patients suffering from hypoparathyroidism.
ENDP: 84.01 (+1.12), SHPG: 239.82 (+6.11), NPSP: 45.88 (+0.03), BIOD: 1.38 (-0.14)
NPS PHARMACEUTICALS INVESTOR ALERT: Faruqi & Faruqi, LLP Announces the Investigation of NPS Pharmaceuticals, Inc. (NPSP) Over the Proposed Sale of the Company to Shire PLC
Business Wire - Tue Jan 27, 1:37PM CST
Juan E. Monteverde, a partner at Faruqi & Faruqi, LLP, a leading national securities firm headquartered in New York City, is investigating the Board of Directors of NPS Pharmaceuticals, Inc. ("NPS" or the "Company"
(Nasdaq: NPSP) for potential breaches of fiduciary duties in connection with the sale of the Company to Shire PLC ("Shire" (Nasdaq: SHPG) for approximately $5.2 billion. The Company's stockholders will only receive $46 for each share of NPS common stock they own. Given the recent FDA approval of NPS's Natpara, a drug to control low blood calcium levels related to hypoparathyroidism, the Company's value could be much higher than the tender offer price. SHPG: 239.82 (+6.11), NPSP: 45.88 (+0.03)
Pfizer, Inc. Should Forget AstraZeneca and Buy This Company Instead
Motley Fool Staff, Leo Sun, George Budwell, and Cheryl Swanson - Motley Fool - Tue Jan 27, 6:56AM CST
Source: Pfizer Inc via Facebook. Pfizer Inc. 's failed bid to acquire U.K.-based AstraZeneca last year suggests that dealmakers are hard at work identifying new acquisition targets for the global drugmaker. If so, investors are right to ponder...
BIIB: 391.66 (-0.45), ESRX: 84.90 (+0.40), ISIS: 63.86 (-0.43), GILD: 101.90 (+1.10), SHPG: 239.82 (+6.11), PFE: 34.64 (-0.23), AZN: 69.96 (+0.20), NPSP: 45.88 (+0.03), ABBV: 58.05 (+1.00), GSK: 47.94 (+1.99)
Shire's Elvanse Gets Positive Response for ADHD in Adults - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jan 26, 4:20PM CST
Shire plc (SHPG) recently announced that it has received a positive response from the European Decentralised Procedure for the use of ADHD drug Elvanse in adults in three European countries.
SHPG: 239.82 (+6.11), SCMP: 15.32 (+0.04), NPSP: 45.88 (+0.03), BIOD: 1.38 (-0.14)
